Durata reports positive data for dalbavancin; Basilea asked to repay shareholders;

 @FierceBiotech: In case you missed it last week: Fierce's Top 10 Biotech Techies - 2013. Special Report | Follow @FierceBiotech

@JohnCFierce: Royalty offer of $6.5B for Elan is smart. Investors can choose cash or Kelly Martin? No brainer. Just sweeten and stir. News | Follow @JohnCFierce

@RyanMFierce: Genentech opens mobile app playbook for tablet fans. Story | Follow @RyanMFierce

> Durata Therapeutics ($DRTX) says that a late-stage study of its antibiotic dalbavancin hit its primary endpoint of non-inferiority. Release

> Basilea, which is awaiting word on regulatory approval for the antibiotic ceftobiprole, has been asked to repay shareholders $5.40 per registered share from its capital reserves. Story

> PatientsLikeMe has grabbed a $1.9 million grant from the Robert Wood Johnson Foundation to spearhead an effort that puts patients at the center of developing health outcome measures, which have traditionally been the domain of medical experts. Story

Pharma News

@FiercePharma: Reckitt Benckiser's heroin addiction drug Suboxone gets 2 generic rivals, despite co's attempt to block them. More | Follow @FiercePharma

@EricPFierce: Qualicaps, which Mitsubishi is buying, is investing $26 million to expand a plant in North Carolina. Article | Follow @EricPFierce

@AlisonBFierce: The FDA rejected Dynavax's Heplisav, an adult hepatitis B vaccine, causing shares to slide as much as 38%. News | Follow @AlisonBFierce

> Pfizer eyes more Chinese partners to speed growth. Article

> Ranbaxy back in gear for generic Lipitor production. News

> Allergan CEO nabs 51% pay hike with $9.4M one-time bonus. Story

> Affymax, Takeda pull Omontys after 3 deaths. Report

Medical Device News

 @FierceMedDev: Intersect ENT pulls in $30M Series D for sinusitis-implant sales push. More | Follow @FierceMedDev

 @MarkHFierce: Another successful post-marketing test will help fuel adoption of CardioDx's coronary artery disease Dx. News | Follow @MarkHFierce

 @DamianFierce: Despite the uptick in scrutiny, Indian clinical trial deaths were about the same in 2012 as in 2011. Story | Follow @DamianFierce

> NeuroPace wins FDA panel vote for epilepsy implant. More

> Philips spinout grabs $9.9M for Parkinson's DBS trial. Article

> Biotronik nabs FDA nod for single-lead ICD. Report

CRO News

> Chinese CRO ShangPharma one step closer to going private. Item

> Moody's says Quintiles is worth $4B, but IPO price remains mystery. Story

> Lonza inks $6.9M stem cell supply deal with NIH. News

> After Warnex buy, Biotrial jumps into bioanalytics. More

> Indian clinical trial deaths unchanged from 2011. Report

Biotech IT News

> Genentech opens mobile app playbook for tablet fans. News

> Medidata grabs software deal with Purdue Pharma. Article

> Ex-Merck dreamer Friend sharpens open science nonprofit with 'competition' edge. Story

> Boost in sales, customers pumps up Medidata's 2012 revenue. More

And Finally… Researchers say they have discovered that a once-a-month, high-dose injection of a commonly used asthma drug--omalizumab--is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. Release

 

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.